LivaNova (NASDAQ:LIVN) Price Target Raised to $93.00

LivaNova (NASDAQ:LIVN) had its price objective lifted by Needham & Company LLC from $81.00 to $93.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. They currently have a buy rating on the stock.

LIVN has been the topic of a number of other reports. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Robert W. Baird cut their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Mizuho raised their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. KeyCorp lifted their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Finally, Barclays boosted their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $83.50.

LivaNova Price Performance

Shares of LivaNova stock opened at $76.22 on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.11. LivaNova has a fifty-two week low of $48.57 and a fifty-two week high of $85.76. The firm has a fifty day moving average price of $79.64 and a two-hundred day moving average price of $70.75. The company has a market cap of $4.20 billion, a PE ratio of 22.55 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.17. The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.05 EPS. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. Analysts expect that LivaNova will post 3.75 EPS for the current year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.35% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently modified their holdings of the stock. Peregrine Capital Management LLC bought a new position in LivaNova during the 4th quarter valued at about $3,830,000. F m Investments LLC boosted its position in LivaNova by 46.9% in the fourth quarter. F m Investments LLC now owns 114,458 shares of the company’s stock valued at $7,043,000 after buying an additional 36,543 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in LivaNova during the third quarter worth about $1,746,000. Vanguard Group Inc. grew its stake in LivaNova by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after buying an additional 34,812 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB increased its holdings in shares of LivaNova by 258.5% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock worth $11,691,000 after buying an additional 137,000 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.